董事會會議召開日期 達芙妮國際控股有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將 於二零二六年三月二十四日（星期二）舉行董事會會議，藉以（其中包括）批准本公 司及其附屬公司截至二零二五年十二月三十一日止年度之全年業績及其刊發，以及考 慮建議派發末期股息（如有）。 承董事會命 達芙妮國際控股有限公司 公司秘書 張晋熙 香港，二零二六年三月十二日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 DAPHNE INTERNATIONAL HOLDINGS LIMITED 達芙妮國際控股有限公司 * ( 於開曼群島註冊成立之有限公司 ) (股份代號： 210) 於本公告日期，本公司董事會包括三位執行董事，分別為張智凱先生、張智喬先生及 張椀絢女士；一位非執行董事，王俊剛先生；以及三位獨立非執行董事，分別為韓炳 祖先生、談大成先生及許文冠女士。 * 僅供識別 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 本月底法定/註冊股本總額： HKD 1,000,000,000 FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 公司名稱: 達芙妮國際控股有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00210 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 達芙妮國際控股有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00210 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD ...

Core Viewpoint - Wohuah Pharmaceutical (002107.SZ) has reported a significant increase in net profit for 2025, achieving a 162.93% year-on-year growth, marking the highest increase in nearly a decade, amidst a challenging industry environment [1] Group 1: Financial Performance - In 2025, Wohuah Pharmaceutical achieved total operating revenue of 817 million yuan, representing a year-on-year growth of 6.96% [1] - The net profit attributable to shareholders reached 95.72 million yuan, reflecting a substantial increase of 162.93% [1] - The net cash flow from operating activities increased by 40.45% year-on-year, indicating strong cash generation capabilities [1] Group 2: Strategic Initiatives - The company has implemented a robust strategy focusing on its unique product line, particularly in the cardiovascular and chronic disease sectors [1] - Wohuah Pharmaceutical plans to optimize its production system in 2025, enhancing operational efficiency and supply chain resilience through resource collaboration and technological upgrades [2] - The company aims to deepen its focus on proprietary products and expand its market presence while maintaining a strong financial structure for potential capital operations [2] Group 3: Market Outlook - The Chinese traditional medicine market is expected to continue its rapid growth, supported by favorable policies and the introduction of new products [2] - The company is committed to refining its management practices to improve operational efficiency and shareholder returns [2]

Core Viewpoint - Wohuah Pharmaceutical (002107.SZ) has reported a significant increase in net profit for 2025, achieving a 162.93% year-on-year growth, marking the highest increase in nearly a decade, despite a challenging industry environment [2] Group 1: Financial Performance - In 2025, Wohuah Pharmaceutical achieved total revenue of 817 million yuan, representing a year-on-year growth of 6.96% [2] - The net profit attributable to shareholders reached 95.72 million yuan, reflecting a substantial increase of 162.93% [2] - The net cash flow from operating activities increased by 40.45% year-on-year, indicating strong cash generation capabilities [2] Group 2: Strategic Initiatives - The company has maintained a "strong exclusive product line" strategy, focusing on proprietary products in the cardiovascular and chronic disease sectors [2] - Wohuah Pharmaceutical plans to implement a strategic optimization and restructuring of its production system in 2025, aiming for efficient integration and cost reduction [3] - The company intends to deepen its focus on proprietary product lines and enhance clinical value and market synergy while responding to ongoing procurement policies [3] Group 3: Future Outlook - Wohuah Pharmaceutical aims to strengthen its research and access strategies, leveraging a solid financial structure for potential capital operations around its core business [3] - The company is expected to continue benefiting from favorable policies supporting the traditional Chinese medicine market, which is projected to maintain rapid growth [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 達芙妮國際控股有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00210 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HK ...

Core Viewpoint - The control of Cangzhou Mingzhu (002108) is set to change, with Guangzhou Light Industry becoming the new controlling shareholder, and the actual controller will be the Guangzhou State-owned Assets Supervision and Administration Commission [1][2]. Group 1: Share Transfer Details - Guangzhou Light Industry will acquire 166,539,465 shares from Dongsu Group, representing 10.10% of the total share capital as of the agreement date [1]. - Dongsu Group and its concerted parties will delegate voting rights for an additional 159,609,160 shares (9.68% of total share capital) to Guangzhou Light Industry, giving it a total voting power of 19.78% in the company [1][2]. - As of the announcement date, Dongsu Group holds 313,912,903 shares (19.04% of total share capital) and is the current controlling shareholder [2]. Group 2: Company Background and Performance - Cangzhou Mingzhu was established in 1995 and operates six wholly-owned subsidiaries, two holding subsidiaries, two branches, and three associated companies, with major industrial parks in Cangzhou and production bases in Shandong, Anhui, and Chongqing [2]. - The company has faced performance pressure in recent years, with negative growth in net profit since the third quarter of 2023, although there was a slight increase of 0.99% in net profit year-on-year for the first three quarters, and revenue grew by 5.90% to 2.078 billion yuan [2][3]. - The sales revenue of PE pipe products has decreased compared to the previous year, while BOPA film products have seen an increase in both sales volume and revenue, with improved profitability [3]. Group 3: Market Reaction - Following the announcement, Cangzhou Mingzhu's stock opened nearly 4% higher on December 16 but later retreated, closing with a 1.29% increase at 4.72 yuan per share, giving it a market capitalization of 7.78 billion yuan [3].

Group 1 - Daphne International (00210) announced that Executive Director Wang Jungang has been reassigned to Non-Executive Director and will resign as Chief Operating Officer, effective December 11, 2025 [1]

Core Viewpoint - Daphne International (00210) announced that Executive Director Mr. Wang Jun Gang has been reassigned to Non-Executive Director and will resign as the Chief Operating Officer, effective from December 11, 2025 [1] Group 1 - The company is undergoing a leadership change with Mr. Wang Jun Gang stepping down from his operational role to focus on other commitments [1]

Group 1 - The core point of the article is the announcement by Daphne International (00210.HK) regarding the change in its executive leadership, specifically the transition of Executive Director Wang Jungang to a non-executive director role and his resignation as Chief Operating Officer, effective December 11, 2025 [1]